Displaying drugs 5451 - 5475 of 11629 in total
ATU-027
Atu027 has been used in trials studying the treatment of Advanced Solid Tumors.
Investigational
ABT-751
ABT-751 has been investigated for the treatment of Lung Cancer, Non-Small Cell Lung Cancer, and Non-Small-Cell Lung Cancer.
Investigational
ATX-914
Axt914 is under investigation in clinical trial NCT00417261 (Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.).
Investigational
ABX-464
ABX-464 is under investigation in clinical trial NCT03905109 (Safety Evaluation of ABX464 in Patients With Moderate to Severe Active Crohn's Disease).
Investigational
NOP-1A
NOP-1A is under investigation in clinical trial NCT01198197 (PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A).
Investigational
ATB-346
ATB-346 is under investigation in clinical trial NCT03220633 (Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects).
Investigational
ALT-801
ALT-801 is under investigation in clinical trial NCT01478074 (ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia).
Investigational
AIM-102
AIM-102 is under investigation in clinical trial NCT01501942 (Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma).
Investigational
AMG-319
Investigational
ANX-005
Investigational
AML-2-23
Investigational
APL-502
APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).
Investigational
Matched Description: … APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death …
Ajoene
Investigational
ACP-015
Investigational
ATI-355
ATI-355 is a humanized anti-Nogo-A antibody developed by Novartis.
Investigational
Matched Description: … ATI-355 is a humanized anti-Nogo-A antibody developed by Novartis. …
ABO-201
Investigational
AUM-302
Investigational
AMP-101
AMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human Dok-7 protein. It is under investigation for the treatment of Dok-7-associated myasthenia.
Investigational
Matched Description: … AMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human …
AV-0113
AV-0113 consists of IL-12 secreting dendritic cells loaded with autologous tumor lysate.
Investigational
AVB-101
AVB-101 is a recombinant AAV9 vector encoding the human progranulin (PGRN) gene.
Investigational
Matched Description: … AVB-101 is a recombinant AAV9 vector encoding the human progranulin (PGRN) gene. …
ASC-618
ASC-618 is a recombinant adeno-associated virus serotype 8 (rAAV2/8) vector expressing bioengineered B domain deleted liver-codon-optimized human factor VIII.
Investigational
Matched Description: … ASC-618 is a recombinant adeno-associated virus serotype 8 (rAAV2/8) vector expressing bioengineered …
AVB-001
AVB-001 is an encapsulated, engineered human ARPE-19 cell line that constitutively expresses the native human IL-2 cytokine
Investigational
ALT-P1
ALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. It is under investigation for the treatment of growth hormone deficiency.
Investigational
Matched Description: … ALT-P1 is a long-acting recombinant human growth hormone fused to an alpha1-antitrypsin variant. …
APG-157
APG-157 consists of zinflavonoids being investigated for the treatment of cancers.
Investigational
Nutraceutical
APD-209
Investigational
Displaying drugs 5451 - 5475 of 11629 in total